Biotechnology's Top 50 in Pharmaceuticals and Diagnostics: A Competitive Analysis (2001 Edition) - Market Research Reports

Contents:

BIOTECHNOLOGY’S TOP 50 IN PHARMACEUTICALS AND DIAGNOSTICS A COMPETITIVE ANALYSIS (2001 EDITION)

TABLE OF CONTENTS

EXECUTIVE SUMMARY................................................................................................................................... I
SECTION 1 ABGENIX.................................................................................................................................... 1-1
1.1 EXECUTIVE SUMMARY........................................................................................................................................... 1-1
1.2 FINANCIAL SUMMARY ............................................................................................................................................ 1-4
1.3 PRODUCT DEVELOPMENT DIRECTION......................................................................................................1-10
1.4 MARKET DIRECTION.............................................................................................................................................1-19
1.5 BUSINESS DEVELOPMENT ACTIVITY...........................................................................................................1-19
SECTION 2 ACAMBIS .................................................................................................................................... 2-1
2.1 EXECUTIVE SUMMARY........................................................................................................................................... 2-1
2.2 FINANCIAL SUMMARY ............................................................................................................................................ 2-3
2.3 PRODUCT DEVELOPMENT DIRECTION........................................................................................................ 2-6
2.4 MARKET DIRECTION.............................................................................................................................................2-12
2.5 BUSINESS DEVELOPMENT ACTIVITY...........................................................................................................2-13
SECTION 3 ADVANCED TISSSUE SCIENCES ............................................................................................ 3-1
3.1 EXECUTIVE SUMMARY........................................................................................................................................... 3-1
3.2 FINANCIAL SUMMARY ............................................................................................................................................ 3-7
3.3 PRODUCT DEVELOPMENT DIRECTION......................................................................................................3-12
3.4 MARKET DIRECTION.............................................................................................................................................3-17
3.5 BUSINESS DEVELOPMENT ACTIVITY...........................................................................................................3-20
SECTION 4 AFFYMETRIX ............................................................................................................................. 4-1
4.1 EXECUTIVE SUMMARY........................................................................................................................................... 4-1
4.2 FINANCIAL SUMMARY ............................................................................................................................................ 4-4
4.3 PRODUCT DEVELOPMENT DIRECTION......................................................................................................4-10
4.4 MARKET DIRECTION.............................................................................................................................................4-15
4.5 BUSINESS DEVELOPMENT ACTIVITY...........................................................................................................4-19
SECTION 5 ALEXION.................................................................................................................................... 5-1
5.1 EXECUTIVE SUMMARY........................................................................................................................................... 5-1
5.2 FINANCIAL SUMMARY ............................................................................................................................................ 5-3
5.3 PRODUCT DEVELOPMENT DIRECTION........................................................................................................ 5-8
5.4 MARKET DIRECTION.............................................................................................................................................5-19
5.5 BUSINESS DEVELOPMENT ACTIVITY...........................................................................................................5-20
SECTION 6 AMGEN....................................................................................................................................... 6-1
6.1 EXECUTIVE SUMMARY........................................................................................................................................... 6-1
6.2 FINANCIAL SUMMARY ............................................................................................................................................ 6-5
6.3 PRODUCT DEVELOPMENT DIRECTION........................................................................................................ 6-8
6.4 MARKET DIRECTION.............................................................................................................................................6-16
6.5 BUSINESS DEVELOPMENT ACTIVITY...........................................................................................................6-23
SECTION 7 AVANT ........................................................................................................................................ 7-1
7.1 EXECUTIVE SUMMARY........................................................................................................................................... 7-1
7.2 FINANCIAL SUMMARY ............................................................................................................................................ 7-4
7.3 PRODUCT DEVELOPMENT DIRECTION........................................................................................................ 7-8
7.4 MARKET DIRECTION.............................................................................................................................................7-16
7.5 BUSINESS DEVELOPMENT ACTIVITY...........................................................................................................7-17
SECTION 8 AVIRON...................................................................................................................................... 8-1
8.1 EXECUTIVE SUMMARY........................................................................................................................................... 8-1
8.2 FINANCIAL SUMMARY ............................................................................................................................................ 8-4
8.3 PRODUCT DEVELOPMENT DIRECTION......................................................................................................8-10
8.4 MARKET DIRECTION.............................................................................................................................................8-16
8.5 BUSINESS DEVELOPMENT ACTIVITY...........................................................................................................8-17
SECTION 9 AXYS............................................................................................................................................ 9-1
9.1 EXECUTIVE SUMMARY........................................................................................................................................... 9-1
9.2 FINANCIAL SUMMARY ............................................................................................................................................ 9-3
9.3 PRODUCT DEVELOPMENT DIRECTION........................................................................................................ 9-9
9.4 MARKET DIRECTION.............................................................................................................................................9-15
9.5 BUSINESS DEVELOPMENT ACTIVITY...........................................................................................................9-16
SECTION 10 BIOGEN .................................................................................................................................. 10-1
10.1 EXECUTIVE SUMMARY.........................................................................................................................................10-1
10.2 FINANCIAL SUMMARY ..........................................................................................................................................10-4
10.3 PRODUCT DEVELOPMENT DIRECTION......................................................................................................10-8
10.4 MARKET DIRECTION...........................................................................................................................................10-14
10.5 BUSINESS DEVELOPMENT ACTIVITY.........................................................................................................10-19
SECTION 11 BIO-TECHNOLOGY GENERAL ............................................................................................11-1
11.1 EXECUTIVE SUMMARY.........................................................................................................................................11-1
11.2 FINANCIAL SUMMARY ..........................................................................................................................................11-3
11.3 PRODUCT DEVELOPMENT DIRECTION......................................................................................................11-7
11.4 MARKET DIRECTION...........................................................................................................................................11-12
11.5 BUSINESS DEVELOPMENT ACTIVITY.........................................................................................................11-17
SECTION 12 BIOVECTOR THERAPEUTICS............................................................................................. 12-1
12.1 EXECUTIVE SUMMARY.........................................................................................................................................12-1
12.2 FINANCIAL SUMMARY ..........................................................................................................................................12-2
12.3 PRODUCT DEVELOPMENT DIRECTION......................................................................................................12-3
12.4 MARKET DIRECTION.............................................................................................................................................12-7
12.5 BUSINESS DEVELOPMENT ACTIVITY...........................................................................................................12-8
SECTION 13 CELL GENESYS ...................................................................................................................... 13-1
13.1 EXECUTIVE SUMMARY.........................................................................................................................................13-1
13.2 FINANCIAL SUMMARY ..........................................................................................................................................13-3
13.3 PRODUCT DEVELOPMENT DIRECTION......................................................................................................13-8
13.4 MARKET DIRECTION...........................................................................................................................................13-15
13.5 BUSINESS DEVELOPMENT ACTIVITY.........................................................................................................13-16
SECTION 14 CELLTECH GROUP PLC....................................................................................................... 14-1
14.1 EXECUTIVE SUMMARY.........................................................................................................................................14-1
14.2 FINANCIAL SUMMARY ..........................................................................................................................................14-5
14.3 PRODUCT DEVELOPMENT DIRECTION....................................................................................................14-10
14.4 MARKET DIRECTION...........................................................................................................................................14-17
14.5 BUSINESS DEVELOPMENT ACTIVITY.........................................................................................................14-23
SECTION 15 CHIRON CORPORATION..................................................................................................... 15-1
15.1 EXECUTIVE SUMMARY.........................................................................................................................................15-1
15.2 FINANCIAL SUMMARY ..........................................................................................................................................15-5
15.3 PRODUCT DEVELOPMENT DIRECTION....................................................................................................15-11
15.4 MARKET DIRECTION...........................................................................................................................................15-17
15.5 BUSINESS DEVELOPMENT ACTIVITY.........................................................................................................15-27
SECTION 16 COR THERAPEUTICS............................................................................................................ 16-1
16.1 EXECUTIVE SUMMARY.........................................................................................................................................16-1
16.2 FINANCIAL SUMMARY ..........................................................................................................................................16-3
16.3 PRODUCT DEVELOPMENT DIRECTION......................................................................................................16-7
16.4 MARKET DIRECTION...........................................................................................................................................16-11
16.5 BUSINESS DEVELOPMENT ACTIVITY.........................................................................................................16-16
SECTION 17 CORIXA ................................................................................................................................... 17-1
17.1 EXECUTIVE SUMMARY.........................................................................................................................................17-1
17.2 FINANCIAL SUMMARY ..........................................................................................................................................17-3
17.3 PRODUCT DEVELOPMENT DIRECTION......................................................................................................17-8
17.4 MARKET DIRECTION...........................................................................................................................................17-20
17.5 BUSINESS DEVELOPMENT ACTIVITY.........................................................................................................17-21
SECTION 18 CORVAS................................................................................................................................... 18-1
18.1 EXECUTIVE SUMMARY.........................................................................................................................................18-1
18.2 FINANCIAL SUMMARY ..........................................................................................................................................18-3
18.3 PRODUCT DEVELOPMENT DIRECTION......................................................................................................18-7
18.4 MARKET DIRECTION...........................................................................................................................................18-14
18.5 BUSINESS DEVELOPMENT ACTIVITY.........................................................................................................18-16
SECTION 19 CUBIST.................................................................................................................................... 19-1
19.1 EXECUTIVE SUMMARY.........................................................................................................................................19-1
19.2 FINANCIAL SUMMARY ..........................................................................................................................................19-5
19.3 PRODUCT DEVELOPMENT DIRECTION......................................................................................................19-9
19.4 MARKET DIRECTION...........................................................................................................................................19-14
19.5 BUSINESS DEVELOPMENT ACTIVITY.........................................................................................................19-15
SECTION 20 CURIS ...................................................................................................................................... 20-1
20.1 EXECUTIVE SUMMARY.........................................................................................................................................20-1
20.2 FINANCIAL SUMMARY ..........................................................................................................................................20-3
20.3 PRODUCT DEVELOPMENT DIRECTION......................................................................................................20-7
20.4 MARKET DIRECTION...........................................................................................................................................20-14
20.5 BUSINESS DEVELOPMENT ACTIVITY.........................................................................................................20-14
SECTION 21 EOS BIOTECHNOLOGY ....................................................................................................... 21-1
21.1 EXECUTIVE SUMMARY.........................................................................................................................................21-1
21.2 FINANCIAL SUMMARY ..........................................................................................................................................21-3
21.3 PRODUCT DEVELOPMENT DIRECTION......................................................................................................21-5
21.4 MARKET DIRECTION...........................................................................................................................................21-10
21.5 BUSINESS DEVELOPMENT ACTIVITY.........................................................................................................21-12
SECTION 22 GENENTECH........................................................................................................................ 22-1
22.1 EXECUTIVE SUMMARY.........................................................................................................................................22-1
22.2 FINANCIAL SUMMARY ..........................................................................................................................................22-5
22.3 PRODUCT DEVELOPMENT DIRECTION....................................................................................................22-10
22.4 MARKET DIRECTION...........................................................................................................................................22-18
22.5 BUSINESS DEVELOPMENT ACTIVITY.........................................................................................................22-25
SECTION 23 GENZYME.............................................................................................................................. 23-1
23.1 EXECUTIVE SUMMARY.........................................................................................................................................23-1
23.2 FINANCIAL SUMMARY ..........................................................................................................................................23-6
23.3 PRODUCT DEVELOPMENT DIRECTION....................................................................................................23-12
23.4 MARKET DIRECTION...........................................................................................................................................23-21
23.5 BUSINESS DEVELOPMENT ACTIVITY.........................................................................................................23-30
SECTION 24 GERON ................................................................................................................................... 24-1
24.1 EXECUTIVE SUMMARY.........................................................................................................................................24-1
24.2 FINANCIAL SUMMARY ..........................................................................................................................................24-4
24.3 PRODUCT DEVELOPMENT DIRECTION......................................................................................................24-8
24.4 MARKET DIRECTION...........................................................................................................................................24-15
24.5 BUSINESS DEVELOPMENT ACTIVITY.........................................................................................................24-16
SECTION 25 GILEAD SCIENCES................................................................................................................ 25-1
25.1 EXECUTIVE SUMMARY.........................................................................................................................................25-1
25.2 FINANCIAL SUMMARY ..........................................................................................................................................25-3
25.3 PRODUCT DEVELOPMENT DIRECTION......................................................................................................25-8
25.4 MARKET DIRECTION...........................................................................................................................................25-13
25.5 BUSINESS DEVELOPMENT ACTIVITY.........................................................................................................25-19

LIST OF FIGURES

Figure 1-1 Abgenix Revenues............................................................................................................................................... 1-1
Figure 2-1 Acambis Revenues .............................................................................................................................................. 2-1
Figure 3-1 Advanced Tissue Revenues ............................................................................................................................... 3-1
Figure 4-1 Affymetrix Revenues .......................................................................................................................................... 4-1
Figure 5-1 Alexion Revenues................................................................................................................................................ 5-1
Figure 6-1 Amgen Revenues................................................................................................................................................. 6-1
Figure 7-1 Avant Revenues ................................................................................................................................................... 7-1
Figure 8-1 Aviron Revenues ................................................................................................................................................. 8-2
Figure 9-1 AxyS Revenues..................................................................................................................................................... 9-1
Figure 10-1 Biogen Revenues ............................................................................................................................................... 10-1
Figure 11-1 BTG Revenues................................................................................................................................................... 11-1
Figure 13-1 Cell Genesys Revenues..................................................................................................................................... 13-1
Figure 14-1 Celltech Revenues ............................................................................................................................................. 14-2
Figure 15-1 Chiron Revenues ............................................................................................................................................... 15-1
Figure 16-1 COR Therapeutics Revenues .......................................................................................................................... 16-1
Figure 17-1 Corixa Revenues ................................................................................................................................................ 17-2
Figure 18-1 Corvas Revenues ............................................................................................................................................... 18-2
Figure 19-1 Cubist Revenues ................................................................................................................................................ 19-1
Figure 20-1 Curis Revenues .................................................................................................................................................. 20-1
Figure 22-1 Genentech Revenues ........................................................................................................................................ 22-2
Figure 23-1 Genzyme Revenues........................................................................................................................................... 23-2
Figure 24-1 Geron Revenues ................................................................................................................................................ 24-2
Figure 25-1 Gilead Sciences Revenues................................................................................................................................ 25-1

LIST OF TABLES

Table ES- 1 Biotechnology’s Top 50 in Pharmaceuticals and Diagnostics..........................................................................i
Table ES- 2 Top 50 Biotechnology Companies Ranked by Worldwide Revenues ($ In Millions)................................iii
Table ES- 3 Top 50 Biotechnology Companies 2000 Total Revenues ($ In Millions) ....................................................iv
Table ES- 4 Top 50 Biotechnology Companies 2000 Net Income ($ In Millions) ...........................................................v
Table ES- 5 Top 50 Biotechnology Companies Ranked by Funds Raised Through Financing ($ In Millions).........vii
Table ES- 6 Top 50 Biotechnology Companies Ranked by Cash and Short-Term Investments at Year End ($
In Millions) ............................................................................................................................................................viii
Table ES- 7 Top 50 Biotechnology Companies Expected Cash Depletion Date and Burn Rate ($ In Millions).......ix
Table ES- 8 Top 50 Biotechnology Companies Market Capitalization Six Year History ($ In Millions)......................x
Table ES- 9 Top 50 Biotechnology Companies Research & Development Expenditures ($ In Millions) ..................xi
Table ES- 10 Top 50 Biotechnology Companies R&D as % of Total Revenues ($ In Millions) ..................................xiii
Table ES- 11 Top 50 Biotechnology Companies Summary of Product Development Programs and by Early
Stage vs Late Stage Sorted by Total Number of Programs ($ In Millions)................................................xiv
Table ES- 12 Top 50 Biotechnology Companies Summary of Product Development Programs by Therapeutic
Area and by Phase of Development ..................................................................................................................xv
Table ES- 13 Top 50 Biotechnology Companies Product Development Programs by Indication ...............................xxi

Table 1.1 Abgenix At A Glance ......................................................................................................................................... 1-1
Table 1.2 Abgenix Summary of Strategic Activity by Therapeutic Area..................................................................... 1-2
Table 1.3 Abgenix Financial Summary ($ Millions Except Share Data) ..................................................................... 1-5
Table 1.4 Abgenix – Overview of Cash Position ............................................................................................................ 1-6
Table 1.5 Abgenix Financing Activity 1990-2000 ........................................................................................................... 1-7
Table 1.6 Abgenix Number of Product Development Programs by Phase of Development and Therapeutic
Area...................................................................................................................................................................... 1-11
Table 1.7 Abgenix Programs in Development .............................................................................................................. 1-12
Table 1.8 Abgenix Leading Programs ............................................................................................................................. 1-12
Table 1.9 Abgenix Strategic Alliances, Merger/Acquisitions (1996-2001) ............................................................... 1-30
Table 2.1 Acambis At A Glance......................................................................................................................................... 2-1
Table 2.2 Acambis Summary of Strategic Activity by Therapeutic System................................................................ 2-2
Table 2.3 Acambis Financial Summary (£ Millions Except Share Data) .................................................................... 2-4
Table 2.4 Acambis – Overview of Cash Position............................................................................................................ 2-5
Table 2.5 Acambis Financing Activity 1990-2000........................................................................................................... 2-6
Table 2.6 Acambis Number of Product Development Programs by Phase of Development and Therapeutic
Area........................................................................................................................................................................ 2-8
Table 2.7 Acambis Programs in Development................................................................................................................ 2-8
Table 2.8 Acambis Therapeutics Leading Programs....................................................................................................... 2-9
Table 2.9 Acambis Strategic Alliances, Merger/Acquisitions (1997-2001)............................................................... 2-16
Table 3.1 Advanced Tissue Sciences At A Glance.......................................................................................................... 3-1
Table 3.2 Advanced Tissue Sciences Summary of Strategic Activity by Therapeutic System................................. 3-3
Table 3.3 Advanced Tissue Sciences Financial Summary ($ Millions Except Share Data)...................................... 3-9
Table 3.4 Advanced Tissue Sciences – Overview of Cash Position ........................................................................ 3-10
Table 3.5 Advanced Tissue Sciences Financing Activity 1990-2000 ......................................................................... 3-11
Table 3.6 Advanced Tissue Sciences Number of Product Development Programs by Phase of Development and Therapeutic Area.............................................................................................................. 3-14
Table 3.7 Advanced Tissue Sciences Programs in Development............................................................................... 3-14
Table 3.8 Advanced Tissue Sciences Leading Programs.............................................................................................. 3-15
Table 3.9 Advanced Tissue Sciences Worldwide Sales of Pharmaceuticals and Diagnostics ($ Millions).......... 3-17
Table 3.10 Advanced Tissue Sciences New Product Approvals (1996-2001)............................................................ 3-20
Table 3.11 Advanced Tissue Sciences Strategic Alliances, Merger/Acquisitions (1996-2001) ............................... 3-21
Table 4.1 Affymetrix At A Glance..................................................................................................................................... 4-1
Table 4.2 Affymetrix Summary of Strategic Activity by Therapeutic System............................................................ 4-2
© 2001 Adis International, POV Reports.
May not be reproduced without written permission.
Table 4.3 Affymetrix Financial Summary ($ Millions Except Share Data)................................................................. 4-5
Table 4.4 Affymetrix Overview of Cash Position........................................................................................................... 4-6
Table 4.5 Affymetrix Financing Activity 1990-2000....................................................................................................... 4-8
Table 4.6 Affymetrix Number of Product Development Programs by Phase of Development and
Therapeutic Area ............................................................................................................................................... 4-12
Table 4.7 Affymetrix Product Development Programs............................................................................................... 4-12
Table 4.8 Affymetrix Leading Programs......................................................................................................................... 4-13
Table 4.9 Affymetrix Worldwide Sales of Pharmaceuticals and Diagnostics ($ Millions) ..................................... 4-16
Table 4.10 Affymetrix Strategic Alliances, Mergers/Acquisitions 1996-2001............................................................ 4-24
Table 5.1 Alexion At A Glance .......................................................................................................................................... 5-1
Table 5.2 Alexion Summary of Strategic Activity by Therapeutic System.................................................................. 5-2
Table 5.3 Alexion Financial Summary ($ Millions Except Share Data) ...................................................................... 5-5
Table 5.4 Alexion – Overview of Cash Position............................................................................................................ 5-6
Table 5.5 Alexion Financing Activity 1990-2000 ............................................................................................................ 5-7
Table 5.6 Alexion Number of Product Development Programs by Phase of Development and Therapeutic
Area........................................................................................................................................................................ 5-9
Table 5.7 Alexion Programs in Development................................................................................................................ 5-10
Table 5.8 Alexion Leading Programs .............................................................................................................................. 5-11
Table 5.9 Alexion Strategic Alliances, Merger/Acquisitions (1996-2001) ................................................................ 5-22
Table 6.1 Amgen At A Glance ........................................................................................................................................... 6-1
Table 6.2 Amgen Summary of Strategic Activity by Therapeutic System................................................................... 6-2
Table 6.3 Amgen Financial Summary ($ Millions Except Share Data) ....................................................................... 6-5
Table 6.4 Amgen – Overview of Cash Position............................................................................................................. 6-7
Table 6.5 Amgen Financing Activity 1990-2000 ............................................................................................................. 6-7
Table 6.6 Amgen Number of Product Development Programs by Phase of Development and Therapeutic
Area...................................................................................................................................................................... 6-10
Table 6.7 Amgen Programs in Development ................................................................................................................ 6-10
Table 6.8 Amgen Leading Programs ............................................................................................................................... 6-11
Table 6.9 Amgen Worldwide Sales of Pharmaceuticals and Diagnostics ($ Millions)............................................ 6-16
Table 6.10 Amgen New Product Approvals (1997-2001).............................................................................................. 6-22
Table 6.11 Amgen Strategic Alliances, Merger/Acquisitions (1996-2001) ................................................................. 6-25
Table 7.1 Avant At A Glance.............................................................................................................................................. 7-1
Table 7.2 Avant Summary of Strategic Activity by Therapeutic System..................................................................... 7-2
Table 7.3 Avant Financial Summary ($ Millions Except Share Data) ......................................................................... 7-5
Table 7.4 Avant – Overview of Cash Position ................................................................................................................ 7-6
Table 7.5 Avant Financing Activity 1990-2000 ............................................................................................................... 7-7
Table 7.6 Avant Number of Product Development Programs by Phase of Development and Therapeutic
Area........................................................................................................................................................................ 7-9
Table 7.7 Avant Immunotherapeutics Programs in Development ............................................................................ 7-11
Table 7.8 Avant Leading Programs.................................................................................................................................. 7-12
Table 7.9 Avant Immunotherapy Strategic Alliances, Mergers/Acquisitions 1996-2001 ...................................... 7-20
Table 8.1 Aviron At A Glance............................................................................................................................................ 8-1
Table 8.2 Aviron Strategic Summary of Activity by Therapeutic System................................................................... 8-3
Table 8.3 Aviron Financial Summary ($ Millions Except Share Data)........................................................................ 8-5
Table 8.4 Aviron – Overview of Cash Position ............................................................................................................. 8-6
Table 8.5 Aviron Financing Activity 1990-2000.............................................................................................................. 8-7
Table 8.6 Aviron Number of Product Development Programs by Phase of Development and Therapeutic
Area...................................................................................................................................................................... 8-11
Table 8.7 Aviron Product Development Programs...................................................................................................... 8-11
Table 8.8 Aviron Leading Programs................................................................................................................................ 8-12
Table 8.9 Aviron Strategic Alliances, Merger/Acquisitions 1996-2001 .................................................................... 8-17
Table 9.1 AxyS At A Glance ............................................................................................................................................... 9-1
Table 9.2 AxyS Summary of Strategic Activity by Therapeutic System...................................................................... 9-3
Table 9.3 AxyS Financial Summary ($ Millions Except Share Data)........................................................................... 9-5
Table 9.4 AxyS – Overview of Cash Position.................................................................................................................. 9-6
Table 9.5 AxyS Financing Activity 1990-2000................................................................................................................. 9-7
Table 9.6 AxyS Number of Product Development Programs by Phase of Development and Therapeutic Area...................................................................................................................................................................... 9-10
Table 9.7 AxyS Programs in Development .................................................................................................................... 9-11
Table 9.8 AxyS Leading Programs................................................................................................................................... 9-11
Table 9.9 AxyS Strategic Alliances, Merger/Acquisitions (1996-2001)..................................................................... 9-21
Table 10.1 Biogen At A Glance.......................................................................................................................................... 10-1
Table 10.2 Biogen Summary of Strategic Activity by Therapeutic System................................................................. 10-2
Table 10.3 Biogen Financial Summary ($ Millions Except Share Data)...................................................................... 10-5
Table 10.4 Biogen – Overview of Cash Position ........................................................................................................... 10-6
Table 10.5 Biogen Financing Activity 1990-2000............................................................................................................ 10-7
Table 10.6 Biogen Number of Product Development Programs by Phase of Development and Therapeutic
Area....................................................................................................................................................................10-10
Table 10.7 Biogen Programs in Development...............................................................................................................10-10
Table 10.8 Biogen Leading Programs..............................................................................................................................10-11
Table 10.9 Biogen Worldwide Sales of Pharmaceuticals and Diagnostics ($ Millions) ..........................................10-14
Table 10.10 Biogen New Product Approvals (1996-2001) ............................................................................................10-19
Table 10.11 Biogen Strategic Alliances, Merger/Acquisitions (1996-2001)................................................................10-21
Table 11.1 BTG At A Glance ............................................................................................................................................. 11-1
Table 11.2 BTG Summary of Strategic Activity by Therapeutic System.................................................................... 11-2
Table 11.3 BTG Financial Summary ($ Millions Except Share Data) ......................................................................... 11-5
Table 11.4 BTG – Overview of Cash Position................................................................................................................ 11-6
Table 11.5 BTG Financing Activity 1990-2000 ............................................................................................................... 11-7
Table 11.6 Bio-Technology General Number of Product Development Programs by Phase of Development and Therapeutic Area ....................................................................................................................................... 11-9
Table 11.7 BTG Programs in Development .................................................................................................................... 11-9
Table 11.8 Bio-Technology General Leading Programs................................................................................................ 11-9
Table 11.9 BTG Worldwide Sales of Pharmaceuticals and Diagnostics ($ Millions)..............................................11-13
Table 11.10 BTG New Product Approvals (1996-2001) ...............................................................................................11-17
Table 11.11 BTG Strategic Alliances, Mergers/Acquisitions 1996-2001 ....................................................................11-19
Table 12.1 Biovector Therapeutics Financing Activity 1990-2000 .............................................................................. 12-2
Table 12.2 Biovector Therapeutics Number of Product Development Programs by Phase of Development and Therapeutic Area ....................................................................................................................................... 12-4
Table 12.3 Biovector Therapeutics Programs in Development.................................................................................... 12-4
Table 12.4 Biovector Therapeutics Leading Programs................................................................................................... 12-5
Table 12.5 Biovector Strategic Alliances, Merger/Acquisitions (1996-2001)............................................................. 12-9
Table 13.1 Cell Genesys At A Glance ............................................................................................................................... 13-1
Table 13.2 Cell Genesys Summary of Strategic Activity by Therapeutic System ...................................................... 13-2
Table 13.3 Cell Genesys Financial Summary ($ Millions Except Share Data) ........................................................... 13-4
Table 13.4 Cell Genesys – Overview of Cash Position.................................................................................................. 13-5
Table 13.5 Cell Genesys Financing Activity 1990-2000 ................................................................................................. 13-6
Table 13.6 Cell Genesys Number of Product Development Programs by Phase of Development and Therapeutic Area .............................................................................................................................................13-10
Table 13.7 Cell Genesys Leading Programs ...................................................................................................................13-11
Table 13.8 Cell Genesys Programs in Development ....................................................................................................13-12
Table 13.9 Cell Genesys Strategic Alliances, Merger/Acquisitions (1996-2001).....................................................13-20
Table 14.1 Celltech At Glance ............................................................................................................................................ 14-1
Table 14.2 Celltech Chiroscience Summary of Strategic Activity by Therapeutic System....................................... 14-3
Table 14.3 CellTech ChiroScience Financial Summary (£ Millions Except Share Data)......................................... 14-8
Table 14.4 CellTech Chiroscience – Overview of Cash Position................................................................................ 14-9
Table 14.5 Celltech Chiroscience Financing Activity 1990-2000................................................................................14-10
Table 14.6 Celltech Number of Product Development Programs by Phase of Development and Therapeutic
Area....................................................................................................................................................................14-11
Table 14.7 Celltech Programs in Development.............................................................................................................14-11
Table 14.8 Celltech Leading Programs............................................................................................................................14-12
Table 14.9 Celltech New Product Approvals (1996-2001) ..........................................................................................14-23
Table 15.1 Chiron At A Glance.......................................................................................................................................... 15-1
Table 15.2 Chiron Summary of Strategic Activity by Therapeutic System................................................................. 15-2
Table 15.3 Chiron Financial Summary ($ Millions Except Share Data)...................................................................... 15-6
Table 15.4 Chiron – Overview of Cash Position ........................................................................................................... 15-7
Table 15.5 Chiron Financing Activity 1990-2000............................................................................................................ 15-8
Table 15.6 Chiron Number of Product Development Programs by Phase of Development and Therapeutic
Area....................................................................................................................................................................15-12
Table 15.7 Chiron Programs in Development...............................................................................................................15-12
Table 15.8 Chiron Leading Programs..............................................................................................................................15-13
Table 15.9 Chiron Worldwide Sales of Pharmaceuticals and Diagnostics ($ In Millions)....................................15-18
Table 15.10 Chiron Strategic Alliances, Merger/Acquisitions ......................................................................................15-36
Table 16.1 COR Therapeutics At A Glance..................................................................................................................... 16-1
Table 16.2 COR Therapeutics Summary of Strategic Activity by Therapeutic System............................................ 16-3
Table 16.3 COR Therapeutics Financial Summary ($ Millions Except Share Data)................................................. 16-5
Table 16.4 COR Therapeutics – Overview of Cash Position ...................................................................................... 16-6
Table 16.5 COR Therapeutics Financing Activity 1990-2000....................................................................................... 16-7
Table 16.6 COR Therapeutics Number of Product Development Programs by Phase of Development and
Therapeutic Area ............................................................................................................................................... 16-8
Table 16.7 COR Therapeutics Programs in Development............................................................................................ 16-9
Table 16.8 COR Therapeutics Leading Programs........................................................................................................... 16-9
Table 16.9 COR Therapeutics Worldwide Sales of Pharmaceuticals and Diagnostics ($ Millions) .....................16-12
Table 16.10 COR Therapeutics New Product Approvals (1997-2001).......................................................................16-14
Table 16.11 COR Therapeutics Strategic Alliances, Merger/Acquisitions (1996—2001) .......................................16-17
Table 17.1 Corixa At A Glance........................................................................................................................................... 17-1
Table 17.2 Corixa Summary of Strategic Activity by Therapeutic System.................................................................. 17-3
Table 17.3 Corixa Financial Summary ($ Millions Except Share Data) ...................................................................... 17-5
Table 17.4 Corixa – Overview of Cash Position ............................................................................................................. 17-6
Table 17.5 Corixa Financing Activity 1990-2000 ............................................................................................................ 17-7
Table 17.6 Corixa Number of Product Development Programs by Phase of Development and Therapeutic
Area....................................................................................................................................................................17-10
Table 17.7 Corixa Programs in Development................................................................................................................17-11
Table 17.8 Corixa Leading Programs...............................................................................................................................17-11
Table 17.9 Corixa Strategic Alliances, Merger/Acquisitions (1997-2001) ................................................................17-28
Table 18.1 Corvas At A Glance.......................................................................................................................................... 18-1
Table 18.2 Corvas Summary of Strategic Activity by Therapeutic System................................................................. 18-2
Table 18.3 Corvas Financial Summary ($ Millions Except Share Data)...................................................................... 18-4
Table 18.4 Corvas – Overview of Cash Position............................................................................................................. 18-5
Table 18.5 Corvas Financing Activity 1990-2000............................................................................................................ 18-6
Table 18.6 Corvas Number of Product Development Programs by Phase of Development and Therapeutic
Area...................................................................................................................................................................... 18-9
Table 18.7 Corvas Programs in Development................................................................................................................. 18-9
Table 18.8 Corvas Leading Programs..............................................................................................................................18-11
Table 18.9 Corvas Strategic Alliances, Merger/Acquisitions (1996-2001)................................................................18-18
Table 19.1 Cubist At A Glance........................................................................................................................................... 19-1
Table 19.2 Cubist Summary of Strategic Activity by Therapeutic System.................................................................. 19-2
Table 19.3 Cubist Financial Summary ($ Millions Except Share Data)....................................................................... 19-6
Table 19.4 Cubist – Overview of Cash Position ............................................................................................................ 19-7
Table 19.5 Cubist Financing Activity 1990-2000............................................................................................................. 19-8
Table 19.6 Cubist Number of Product Development Programs by Phase of Development and Therapeutic
Area....................................................................................................................................................................19-10
Table 19.7 Cubist Programs in Development................................................................................................................19-11
Table 19.8 Cubist Leading Programs...............................................................................................................................19-11
Table 19.9 Cubist Strategic Alliances, Merger/Acquisitions (1996-2001).................................................................19-18
Table 20.1 Curis At A Glance ............................................................................................................................................. 20-1
Table 20.2 Curis Summary of Strategic Activity by Therapeutic System.................................................................... 20-2
Table 20.3 Curis Financial Summary ($ Millions Except Share Data)......................................................................... 20-4
Table 20.4 Curis – Overview of Cash Position................................................................................................................ 20-5
Table 20.5 Curis Financing Activity 1990-2000............................................................................................................... 20-6
Table 20.6 Curis Number of Product Development Programs by Phase of Development and Therapeutic Area...................................................................................................................................................................... 20-9
Table 20.7 Curis Programs in Development ..................................................................................................................20-10
Table 20.8 Curis Leading Programs.................................................................................................................................20-10
Table 20.9 Curis Strategic Alliances, Merger/Acquisitions (1996-2001)...................................................................20-16
Table 21.1 Eos BiotechnologySummary of Strategic Activity by Therapeutic System............................................. 21-2
Table 21.2 Eos Biotechnology Financing Activity 1990 2000 ...................................................................................... 21-4
Table 21.3 Eos Biotechnology Number of Product Development Programs by Phase of Development and Therapeutic Area ............................................................................................................................................... 21-7
Table 21.4 Eos Biotecnology Programs in Development.............................................................................................. 21-8
Table 21.5 Eos Biotechnology Leading Programs .......................................................................................................... 21-8
Table 21.6 Eos Biotechnology Strategic Alliances, Merger/Acquisitions (1996-2001) ..........................................21-15
Table 22.1 Genentech At A Glance................................................................................................................................... 22-1
Table 22.2 Genentech Summary of Strategic Activity by Therapeutic System.......................................................... 22-2
Table 22.3 Genentech Financial Summary ($ Millions Except Share Data)............................................................... 22-6
Table 22.4 Genentech – Overview of Cash Position ..................................................................................................... 22-7
Table 22.5 Genentech Financing Activity 1989-2000..................................................................................................... 22-8
Table 22.6 Genentech Number of Product Development Programs by Phase of Development and Therapeutic Area .............................................................................................................................................22-12
Table 22.7 Genentech Programs in Development........................................................................................................22-13
Table 22.8 Genentech Leading Programs.......................................................................................................................22-13
Table 22.9 Genentech Worldwide Sales of Pharmaceuticals and Diagnostics ($ Millions) ...................................22-19
Table 22.10 Genentech New Product Approvals (1997-2001).....................................................................................22-25
Table 22.11 Genentech Strategic Alliances, Merger/Acquisitions (1997-2001).........................................................22-30
Table 23.1 Genzyme At A Glance ..................................................................................................................................... 23-1
Table 23.2 Genzyme Summary of Strategic Activity by Therapeutic System............................................................ 23-5
Table 23.3 Genzyme Financial Summary ($ Millions Except Share Data) ................................................................. 23-8
Table 23.4 Genzyme – Overview of Cash Position....................................................................................................... 23-9
Table 23.5 Genzyme Financing Activity 1990-2000 .....................................................................................................23-10
Table 23.6 Genzyme Number of Product Development Programs by Phase of Development and
Therapeutic Area .............................................................................................................................................23-13
Table 23.7 Genzyme Programs in Development ..........................................................................................................23-14
Table 23.8 Genzyme Leading Programs .........................................................................................................................23-15
Table 23.9 Genzyme Worldwide Sales of Pharmaceuticals and Diagnostics ($ Millions)......................................23-21
Table 23.10 Genzyme Strategic Alliances, Merger/Acquisitions (1997-2001) ...........................................................23-39
Table 24.1 Geron At A Glance........................................................................................................................................... 24-1
Table 24.2 Geron Summary of Strategic Activity by Therapeutic System.................................................................. 24-3
Table 24.3 Geron Financial Summary ($ Millions Except Share Data)....................................................................... 24-5
Table 24.4 Geron – Overview of Cash Position ............................................................................................................. 24-6
Table 24.5 Geron Financing Activity 1990-2000............................................................................................................. 24-7
Table 24.6 Geron Number of Product Development Programs by Phase of Development and Therapeutic
Area....................................................................................................................................................................24-11
Table 24.7 Geron Programs in Development................................................................................................................24-11
Table 24.8 Geron Leading Programs...............................................................................................................................24-11
Table 24.9 Geron Strategic Alliances, Mergers/Acquisitions 1996-2001..................................................................24-17
Table 25.1 Gilead Sciences At A Glance .......................................................................................................................... 25-1
Table 25.2 Gilead Science Summary of Strategic Activity by Therapeutic System................................................... 25-2
Table 25.3 Gilead Sciences Financial Summary ($ Millions Except Share Data) ...................................................... 25-4
Table 25.4 Gilead Sciences – Overview of Cash Position............................................................................................ 25-6
Table 25.5 Gilead Sciences Financing Activity 1990-2000 ............................................................................................ 25-7
Table 25.6 Gilead Number of Product Development Programs by Phase of Development and Therapeutic
Area....................................................................................................................................................................25-10
Table 25.7 Gilead Sciences Programs in Development................................................................................................25-10
Table 25.8 Gilead Leading Programs...............................................................................................................................25-11
Table 25.9 Gilead Sciences Worldwide Sales of Pharmaceuticals and Diagnostics ($ Millions)...........................25-14
Table 25.10 Gilead Sciences New Product Approvals (1996-2001).............................................................................25-19
Table 25.11 Gilead Sciences Strategic Alliances, Merger/Acquisitions (1997-2001) ................................................25-23